Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.9752W HIGH $14.51
Volume
560.05 K
Value Traded
6.01 M
Short % Float
8.51%
+2.41%Week
-9.59%1 Month
-5.68%3 Month
-27.79%6 Month
-86.43%5 Year
-56.71%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
492.94 M
EPS (TTM)
0.14
P/E Ratio
53.73
Ent. Value
-74.26 M
Total Shares
64.50 M
Float Shares
58.60 M
Insiders
10.38%
Institutions
79.30%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ARVN Catalyst Timeline
Dated clinical, regulatory and corporate events for Arvinas, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Arvinas, Inc.
555Total events
19Upcoming
120Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Late-BreakerARV-102Presentation
Late-breaking oral presentation of Phase 1 ARV-102 oculomotor and biomarker data at MDS 2026
Parkinson's diseasesource ↗
▲Biomarker DataARV-102Clinical Data
CSF LRRK2 reductions correlated with oculomotor and synaptic biomarker changes in Phase 1 ARV-102 trial
Parkinson's diseasesource ↗
▲Oral PresentationARV-102Presentation
Late-breaking oral presentation of Phase 1 ARV-102 oculomotor and biomarker data at MDS 2026
Parkinson's diseasesource ↗
▲Poster PresentationARV-102Presentation
E-Poster presentation of Phase 1 oculomotor and biomarker data for ARV-102 at MDS 2026
Parkinson's diseasesource ↗
▲Full ResultsARV-102Clinical Data
Final Phase 1 data for ARV-102 in Parkinson's disease presented
Parkinson's diseasesource ↗
◆Poster PresentationARV-102Presentation
E-poster presentation of Phase 1 ARV-102 oculomotor and biomarker data at 2026 MDS Congress
Parkinson's diseasesource ↗
▲Poster PresentationARV-102Presentation
E-Poster presentation of Phase 1 ARV-102 oculomotor and biomarker data at MDS 2026
Parkinson's diseasesource ↗
▲First Patient DosedARV-6723Trial
First patient dosed in Phase 1/2 trial of ARV-6723 in advanced solid tumors
advanced solid tumorssource ↗
●Trial InitiationARV-6723Trial
Phase 1/2 clinical trial of ARV-6723 initiated in advanced solid tumors
advanced solid tumorssource ↗
▲FDA ApprovalVEPPANUApprovedFDA Decision
FDA approval of VEPPANU (vepdegestrant)
ER+/HER2-, ESR1-mutated advanced or metastatic breast cancersource ↗
▲Partnership / LicenseVEPPANUApprovedCorporate
Out-licensing of VEPPANU to Rigel Pharmaceuticals
▲Enrollment CompleteARV-806Trial
Completed dose escalation enrollment
solid tumors harboring KRAS G12D mutationssource ↗
▲Trial InitiationARV-027Trial
Initiated enrollment in multiple dose cohorts
healthy volunteerssource ↗
▲Poster PresentationARV-6723Presentation
Presented preclinical data at AACR Annual Meeting demonstrating antitumor activity
solid tumorssource ↗
▲Poster PresentationPresentation
Presented preclinical data for novel pan-KRAS degrader at AACR Special Conference
pancreatic, colorectal, and lung cancersource ↗
◆Partnership / LicenseARV-806Corporate
Announced plans to seek out-licensing agreement for additional clinical trials
▲Other Regulator MilestoneVEPPANUApprovedEx-US Regulatory
NCCN added vepdegestrant (VEPPANU) to Clinical Practice Guidelines as Category 2A treatment option
HR-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancersource ↗
▲Milestone PaymentVEPPANUApprovedCorporate
Development milestone payment from Pfizer upon FDA approval
●Enrollment UpdateARV-393Trial
Continued enrollment in Phase 1 combination trial with glofitamab
diffuse large B-cell lymphomasource ↗
▲Partnership / LicenseARV-102Corporate
Joined LRRK2 Investigative Therapeutics Exchange (LITE) program and Parkinson's Precision Medicine Initiative (PPMI)
Parkinson's diseasesource ↗
▲Preclinical PoCARV-6723Preclinical
Preclinical data presented at AACR Annual Meeting
solid tumorssource ↗
▲Preclinical PoCPreclinical
Preclinical data for novel pan-KRAS degrader presented at AACR Special Conference
pancreatic, colorectal, lung cancersource ↗
◆Trial InitiationARV-6723Trial
Initiate enrollment of Phase 1 clinical trial
advanced solid tumorssource ↗
◆Topline ReadoutARV-393Clinical Data
Share data from early monotherapy cohorts in Phase 1 dose escalation trial at a medical congress
relapsed/refractory non-Hodgkin lymphomasource ↗
◆Topline ReadoutARV-806Clinical Data
Share initial data from Phase 1 monotherapy dose escalation trial
solid tumors harboring KRAS G12D mutationssource ↗
▲PDUFA DateVEPPANUApprovedRegulatory Filing
PDUFA date of June 5, 2026 (approval received ahead of this date)
ER+/HER2- ESR1-mutated advanced or metastatic breast cancersource ↗
◆PDUFA DateVepdegestrantApprovedRegulatory Filing
PDUFA action date for vepdegestrant monotherapy
ER+/HER2- advanced or metastatic breast cancer with ESR1 mutationssource ↗
▲Partnership / LicenseARV-102Corporate
Joined LITE and PPMI programs supported by MJFF
Parkinson's diseasesource ↗
◆Oral PresentationPresentation
Management to participate in fireside chat at Jefferies Global Healthcare Conference
▲Partnership / LicenseVEPPANUApprovedCorporate
License agreement with Rigel for exclusive global rights to VEPPANU
ER+/HER2- ESR1-mutated advanced or metastatic breast cancersource ↗
▲FDA ApprovalVEPPANUApprovedFDA Decision
FDA approval of VEPPANU (vepdegestrant)
ER+/HER2- ESR1-mutated advanced or metastatic breast cancersource ↗
▲Oral PresentationARV-102Presentation
Presented Phase 1 data for ARV-102 at AD/PD 2026
Parkinson's diseasesource ↗
▲Poster PresentationARV-6723Presentation
Presented preclinical data at AACR Immuno-Oncology Conference
Solid tumorssource ↗
▲First Patient DosedARV-027Trial
Initiated dosing with ARV-027 in Phase 1 healthy volunteer trial
Healthy volunteerssource ↗
▲Enrollment CompleteARV-806Trial
Completed dose escalation enrollment in Phase 1 trial of ARV-806
Solid tumors with KRAS G12D mutationssource ↗
▲Trial InitiationARV-393Trial
Initiated Phase 1 combination trial with glofitamab in DLBCL
Diffuse large B-cell lymphomasource ↗
▲FDA ApprovalVEPPANUApprovedFDA Decision
FDA approval of VEPPANU (vepdegestrant)
ER+/HER2- ESR1-mutated advanced or metastatic breast cancersource ↗
▲Primary Endpoint MetVepdegestrantApprovedClinical Data
VERITAC-2 met primary endpoint: PFS improvement in ESR1m population
ER+/HER2- ESR1-mutated advanced or metastatic breast cancersource ↗
▲Full ResultsVepdegestrantApprovedClinical Data
Full results from VERITAC-2 supporting approval
ER+/HER2- ESR1-mutated advanced or metastatic breast cancersource ↗
◆Trial InitiationARV-102Trial
Plans to initiate registrational Phase 2 clinical trial in PSP
progressive supranuclear palsy (PSP)source ↗
◆Trial InitiationARV-6723Trial
ARV-6723 on track to initiate Phase 1 trial in mid-2026
advanced solid tumorssource ↗
◆Enrollment MilestoneARV-393Trial
Arvinas plans to initiate enrollment of a combination cohort with glofitamab in patients with DLBCL in mid-2026
diffuse large B-cell lymphoma (DLBCL)source ↗
◆Biomarker DataARV-102Clinical Data
Share additional biomarker data from Phase 1 trial in Parkinson's disease
Parkinson's diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How ARVN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-07 | ARV-102 | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C46 / 100
Pipeline Score
$490M
Pipeline Value
$751M
Commercial Value
Undervalued
Valuation Signal
5
Drugs Scored
3.3x
rNPV / MCap
Top 25%
Micro Cap(rank 166 of 660)
Percentile Rank
Arvinas, Inc. carries a moderate pipeline score (46/100), with $1.2B risk-adjusted pipeline value, led by ARV-110 in Prostate Cancer Metastatic (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-Q), to Jun 2026) Revenue $316.7M x 2.4 = $751M
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ARV-110 Small moleculeCompletedNCT03888612 | Prostate Cancer Metastatic | Phase 1 | COMPLETED | 248 | Jan 27, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every ARVN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ARV-102 | Parkinson's disease | Phase 1 | 2026-03-18 | greater than 50% LRRK2 degradation in the CSF; approximately 50% or greater reduction of LRRK2 in cerebrospinal fluid (CSF) at all doses by day 14; maintained the reduction through day 28Read More | Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 DaysRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Smaldone Alsup LaurieDirector | Grant/Award | 15,527 41,572 held | $0.00 | 06/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ARVN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 0.1 % (-85.7 %) | 5.88 M | 707.10 K | -70.38% ( -1.68 M) |
ARVN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ARVN ranks across every disease it competes in
Competitive Position is a premium feature
See how ARVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialARVN News
ARVN▲ +1.7%today
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
Arvinas, Inc. presented promising data from a Phase 1 clinical trial of ARV-102 for Parkinson's disease, showing improvements in eye movement and biomarker correlations. The trial indicated that ARV-102 effectively targets LRRK2, relevant to neurodegenerative diseases. The findings support further clinical evaluation of ARV-102, despite the study not being designed to assess clinical efficacy.
Read more →ARVNArvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
Arvinas, Inc. announced that it will present novel biomarker data from its Phase 1 clinical trial of ARV-102 at the 2026 International Congress of Parkinson's Disease and Movement Disorders. The investigational drug targets LRRK2, a protein implicated in Parkinson's disease. Presentations will occur both as oral and e-poster sessions during the congress in Seoul, Korea.
Read more →ARVNArvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Arvinas, Inc. has announced the granting of stock options and restricted stock units to a new employee in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term with an exercise price matching the stock's closing price on the grant date. Arvinas continues to develop innovative therapies through its PROTAC platform, targeting various diseases.
Read more →ARVNArvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
Arvinas, Inc. has announced the dosing of the first patient in its Phase 1/2 clinical trial for ARV-6723, an oral PROTAC targeting HPK1 in advanced solid tumors. This marks Arvinas' first entry into immuno-oncology. Preclinical studies showed promising results, indicating ARV-6723's potential to enhance immune activity and address resistance to existing therapies. The trial will evaluate safety and preliminary antitumor activity.
Read more →ARVNArvinas to Participate in Upcoming Investor Conferences
Arvinas, Inc. announced its participation in several upcoming investor conferences, including the Wells Fargo Healthcare Conference and the Morgan Stanley Annual Global Healthcare Conference. The company is focused on developing therapies using its PROTAC platform, which targets disease-causing proteins. Arvinas is advancing multiple investigational drugs for various conditions, highlighting its commitment to innovation in biotechnology.
Read more →ARVN▲ +11.7%on this news
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Arvinas, Inc. reported strong financial results for Q2 2026, highlighted by the FDA's approval of VEPPANU, the first PROTAC therapy. The company has successfully licensed VEPPANU to Rigel Pharmaceuticals and anticipates sharing clinical data from three Phase 1 programs within the next year. Additionally, promising preclinical data was presented for the HPK1 degrader program, ARV-6723.
Read more →ARVNArvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
Arvinas, Inc. will report its second quarter 2026 financial results on August 4, 2026, during a live webcast. The event will include a corporate update and can be accessed via the company's investor page. Arvinas is known for its innovative PROTAC platform, which targets disease-causing proteins for degradation.
Read more →ARVNArvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
Arvinas, Inc. has joined the LRRK2 Investigative Therapeutics Exchange (LITE) and the Parkinson’s Precision Medicine Initiative (PPMI), programs supported by The Michael J. Fox Foundation. This collaboration aims to advance ARV-102, Arvinas’ investigational treatment targeting LRRK2 for conditions like Parkinson's disease. The initiatives will focus on enhancing understanding of LRRK2 biology and accelerating the development of targeted therapies. Arvinas has a commitment to improving treatments for neurodegenerative diseases through innovative research.
Read more →ARVNArvinas to Present at Jefferies Global Healthcare Conference 2026
Arvinas, Inc. will present at the Jefferies Global Healthcare Conference on June 3, 2026. The company is known for its innovative drug development using targeted protein degradation. They have successfully developed the first FDA-approved PROTAC for treating advanced breast cancer and are advancing multiple investigational drugs for various diseases.
Read more →ARVNArvinas to Present at Jefferies Global Healthcare Conference
Arvinas, Inc. will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026. The company is known for its innovative protein degradation therapies and has developed the first FDA-approved PROTAC for treating advanced breast cancer. Arvinas is also advancing several investigational drugs targeting various diseases.
Read more →ARVNArvinas Employees Give Back During Company-wide Impact Day
Arvinas, a clinical-stage biotechnology company, celebrated its fourth Company-wide Impact Day, where employees engaged in various community service activities across multiple locations. The company emphasizes its commitment to both patients and the communities where it operates. This year's initiatives included preparing meals for patients, creating comforting blankets, and beautifying local spaces. The event demonstrates Arvinas' dedication to making a positive impact. CEO Randy Teel expressed pride in the employees' passion for community service.
Read more →ARVNArvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
Arvinas, Inc. reported its first quarter 2026 financial results and corporate updates, highlighting significant developments including the FDA approval of VEPPANU, a groundbreaking PROTAC for advanced breast cancer. The approval marks a milestone as it is the first of its kind, correlating with Arvinas' long-term focus on targeted protein degradation. Additionally, Phase 1 clinical trials show encouraging results for other drug candidates like ARV-102 for Parkinson's disease. Arvinas is also expanding collaborations and planning further trials, reinforcing its growth trajectory in the biotechnology sector.
Read more →ARVNArvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
Arvinas and Pfizer have entered into a license agreement with Rigel Pharmaceuticals for the exclusive global rights to VEPPANU (vepdegestrant), an FDA-approved PROTAC therapy for certain types of breast cancer. The agreement includes an initial payment of $85 million, with opportunities for additional payments based on development milestones. Rigel will handle commercialization in the U.S., while Arvinas and Pfizer will continue their development efforts. The transaction is subject to necessary regulatory approvals, which could delay the implementation of their plans.
Read more →ARVNArvinas to Report First Quarter 2026 Financial Results on May 12, 2026
Arvinas, Inc. will report its first quarter 2026 financial results and provide a corporate update on May 12, 2026. The live webcast will begin at 8:00 a.m. ET and will be accessible on the company's investor page. Arvinas is known for its innovative protein degradation therapies and has made significant advancements in treating various cancers and neurodegenerative disorders.
Read more →ARVN▲ +6.2%on this newsshared move
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
Arvinas, in partnership with Pfizer, has received FDA approval for VEPPANU (vepdegestrant), marking the first-ever approval of a PROTAC therapy. This drug targets advanced breast cancer in adults with ESR1 mutations, offering a new treatment option for patients who have progressed after initial endocrine therapy. The approval was granted ahead of the scheduled PDUFA date of June 5, 2026, reflecting a significant milestone in the field of oncology. Preliminary clinical trial results indicated improved progression-free survival compared to standard therapies, although some risks associated with treatment remain.
Read more →ARVN▼ -9.3%on this news
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
Arvinas has presented positive Phase 1 clinical trial data for ARV-102, an investigational drug targeting LRRK2 in Parkinson's disease patients. The trial demonstrated a reduction of LRRK2 levels in cerebrospinal fluid by over 50% after 28 days of once-daily dosing. ARV-102 was well tolerated with no serious adverse events reported, supporting its potential for further development in neurodegenerative diseases linked to LRRK2 dysfunction. The data were highlighted during an oral session at the AD/PD™ 2026 conference.
Read more →ARVNArvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Arvinas, Inc. will present Phase 1 clinical trial data for ARV-102 at the 2026 International Conference on Alzheimer's and Parkinson's Diseases. The investigational drug aims to target and degrade LRRK2, a protein implicated in Parkinson’s disease. The company plans to initiate a Phase 1b trial for ARV-102 in progressive supranuclear palsy pending regulatory feedback. The presentation will take place on March 18, 2026, focusing on safety, pharmacokinetics, and pharmacodynamics related to the treatment.
Read more →ARVNArvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Arvinas, Inc. reported its fourth quarter and full year 2025 financial results, highlighting significant advancements in its clinical pipeline, including upcoming data readouts for several investigational drugs. The company has sufficient cash to support operations into 2028, despite a decrease in cash reserves and revenue from collaboration agreements. CEO Randy Teel emphasized the company's strategic focus on addressing unmet medical needs in oncology and neurology.
Read more →About Arvinas, Inc.
Headquarters395 WINCHESTER AVE, NEW HAVEN, CT, 06511
Founded2013
BIOPHARMAWATCH ELITE PLUS
Trade the next ARVN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime